Cinnarizine

General characteristics. Structure:

Active ingredient: 0,025 g of cinnarizine.

Excipients: potato starch, lactose (sugar milk), povidone middlemolecular, silicon dioxide colloid (aerosil), magnesium stearate.

Pharmacological properties:

Pharmacodynamics. The selection blocker of "slow" calcium channels, reduces receipt in cells of calcium ions and reduces their keeping in depot of a plasmolemma, reduces a tone of smooth muscles of arterioles. Directly influencing smooth muscles of vessels, reduces their reaction to biogenic substances (adrenaline, noradrenaline, dopamine, angiotensin, vasopressin). Has vasodilating effect (especially concerning brain vessels), without having significant effect on arterial pressure.

Shows moderate antihistaminic activity, reduces excitability of a vestibular mechanism, lowers a tone of a sympathetic nervous system. It is effective at patients with lateral insufficiency of cerebral circulation, initial atherosclerosis of vessels of a brain and chronic diseases of vessels of a brain with postinsultny focal symptoms. At patients with disturbance of peripheric circulation improves blood supply of bodies and fabrics (including a myocardium), strengthens post-ischemic vasodilatation. Increases elasticity of membranes of erythrocytes, their deformability, reduces viscosity of blood. Increases resistance of muscles to a hypoxia.

Pharmacokinetics. Drug is soaked up in a stomach and intestines. The maximum concentration in a blood plasma after intake in 1-3 hours. Communication of cinnarizine with proteins of plasma makes 91%. It is completely metabolized in a liver (by means of dealkylation). The elimination half-life is equal to 4 hours. It is removed in the form of metabolites: 1/3 – kidneys and 2/3 – with a fecal masses – intestines.

Indications to use:

• symptoms of cerebrovascular insufficiency (dizziness, sonitus, headache, memory disturbance, decrease in concentration of attention);
• vestibular disturbances (including Menyer's disease; dizziness, sonitus, nystagmus, nausea and vomiting of a labyrinth origin);
• prevention of kinetoz ("a road disease" – sea and aeroembolism);
• migraine (prevention of attacks);
• disturbances of peripheric circulation: a Raynaud's disease, the "alternating" lameness, a Crocq's disease, trophic disturbances (including trophic and varicose ulcers).

Route of administration and doses:

Inside, after food. At insufficiency of cerebral circulation: on 25 mg three times a day.

At disturbance of peripheric circulation – on 50-75 mg three times a day.

At vestibular disturbances – on 25 mg three times a day. To children the dose is reduced twice.

The maximum daily dose should not exceed 225 mg (9 tablets) a day. A course of treatment from several weeks to several months.

At a kinetoza (a "road" disease): the adult – on 25 mg for half an hour before the road (if necessary repeated reception of 25 mg in 6 hours). For children of 5 years – ½ doses, recommended to adults.

For children of 5 years – ½ doses, recommended to adults on all indicators. At high sensitivity to drug treatment is begun about ½ doses, increasing it gradually.

Features of use:

Patients with Parkinson's disease should appoint drug only in case advantages of treatment surpass by cinnarizine in the importance possible deterioration in a current of a basic disease.

Due to the antihistaminic effect purpose of cinnarizine should be stopped in 4 days prior to conducting allergy skin test. Cinnarizine can affect result at anti-doping control of athletes (false positive result).

The patient with a lactose intolerance, it is necessary to consider that it enters about composition of medicine.

At prolonged use carrying out a control laboratory research of function of a liver, kidneys is recommended, to peripheral blood.

Influence on ability to drive the car and other working mechanisms: drowsiness development, especially in an initiation of treatment therefore it is necessary to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psikhomorny reactions is possible.

Side effects:

From a nervous system: drowsiness, fatigue, headache, extrapyramidal frustration (tremor of extremities and increase in a muscle tone, hypokinesia), depression.

From the alimentary system: dryness in a mouth, pain in epigastric area, dyspepsia, cholestatic jaundice.

From integuments: perspiration, development of a volchanochnopodobny syndrome, red flat deprive (extremely seldom), skin rash.

Others: allergic reactions, lowering of arterial pressure, increase in body weight.

Interaction with other medicines:

Strengthens the oppressing action on the central nervous system of alcohol, sedatives, tricyclic antidepressants.

Contraindications:

Hypersensitivity, pregnancy, lactation period. Lactose intolerance, lactose intolerance, syndrome of glyukozogalaktozny malabsorption. Children up to 5 years.

With care. Parkinson's disease.

Overdose:

Symptoms: vomiting, drowsiness, tremor, lowering of arterial pressure, coma.

Treatment: the specific antidote does not exist, a gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

List B. To store in the dry, protected from light place. To store in the place, unavailable to children. A period of validity - 2 years. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Tablets of 25 mg. On 10, 50 tablets in a blister strip packaging. On 50 tablets in glass jars. Each can or   1, 2, 5, 10 blister strip packagings with the application instruction in a pack.